Cargando…

Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma

Hepatitis B virus (HBV) infection carries a risk of liver cancer and extrahepatic malignancy. However, the incidence trend and clinical course of malignant lymphoma (ML) in HBV patients are not well known. Data about ML newly diagnosed in chronic hepatitis B (CHB) patients from 2003 to 2016 were col...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Kwang-Il, Jo, Jae-Cheol, Kim, Da-Jung, Jeong, Jee-Yeong, Lee, Sangjin, Lee, Ho-Sup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500776/
https://www.ncbi.nlm.nih.gov/pubmed/36146749
http://dx.doi.org/10.3390/v14091943
_version_ 1784795305585147904
author Seo, Kwang-Il
Jo, Jae-Cheol
Kim, Da-Jung
Jeong, Jee-Yeong
Lee, Sangjin
Lee, Ho-Sup
author_facet Seo, Kwang-Il
Jo, Jae-Cheol
Kim, Da-Jung
Jeong, Jee-Yeong
Lee, Sangjin
Lee, Ho-Sup
author_sort Seo, Kwang-Il
collection PubMed
description Hepatitis B virus (HBV) infection carries a risk of liver cancer and extrahepatic malignancy. However, the incidence trend and clinical course of malignant lymphoma (ML) in HBV patients are not well known. Data about ML newly diagnosed in chronic hepatitis B (CHB) patients from 2003 to 2016 were collected from National Health Insurance Service claims. A total of 13,942 CHB patients were newly diagnosed with ML from 2003 to 2016. The number of patients increased 3.8 times, from 442 in 2003 to 1711 in 2016. The 2-year survival rate of all patients was 76.8%, and the 5-year survival rate was 69.8%. The survival rate of patients taking antivirals due to high viral activity before their diagnosis with ML was significantly lower than that of patients with lower viral activity without antivirals (1 yr—77.3%, 3 yr—64.5%, and 5 yr—58.3% vs. 1 yr—84.0%, 3 yr—73.4%, and 5 yr—68.0%, respectively). The survival rate of patients with liver cirrhosis (LC) at baseline was significantly lower than that of those without LC. Cirrhotic patients taking antivirals before ML diagnosis had a worse prognosis than who did not. High viral activity in CHB patients with ML seems to be useful in predicting the prognosis for survival.
format Online
Article
Text
id pubmed-9500776
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95007762022-09-24 Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma Seo, Kwang-Il Jo, Jae-Cheol Kim, Da-Jung Jeong, Jee-Yeong Lee, Sangjin Lee, Ho-Sup Viruses Article Hepatitis B virus (HBV) infection carries a risk of liver cancer and extrahepatic malignancy. However, the incidence trend and clinical course of malignant lymphoma (ML) in HBV patients are not well known. Data about ML newly diagnosed in chronic hepatitis B (CHB) patients from 2003 to 2016 were collected from National Health Insurance Service claims. A total of 13,942 CHB patients were newly diagnosed with ML from 2003 to 2016. The number of patients increased 3.8 times, from 442 in 2003 to 1711 in 2016. The 2-year survival rate of all patients was 76.8%, and the 5-year survival rate was 69.8%. The survival rate of patients taking antivirals due to high viral activity before their diagnosis with ML was significantly lower than that of patients with lower viral activity without antivirals (1 yr—77.3%, 3 yr—64.5%, and 5 yr—58.3% vs. 1 yr—84.0%, 3 yr—73.4%, and 5 yr—68.0%, respectively). The survival rate of patients with liver cirrhosis (LC) at baseline was significantly lower than that of those without LC. Cirrhotic patients taking antivirals before ML diagnosis had a worse prognosis than who did not. High viral activity in CHB patients with ML seems to be useful in predicting the prognosis for survival. MDPI 2022-08-31 /pmc/articles/PMC9500776/ /pubmed/36146749 http://dx.doi.org/10.3390/v14091943 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seo, Kwang-Il
Jo, Jae-Cheol
Kim, Da-Jung
Jeong, Jee-Yeong
Lee, Sangjin
Lee, Ho-Sup
Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title_full Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title_fullStr Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title_full_unstemmed Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title_short Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma
title_sort chronic hepatitis b viral activity enough to take antiviral drug could predict the survival rate in malignant lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500776/
https://www.ncbi.nlm.nih.gov/pubmed/36146749
http://dx.doi.org/10.3390/v14091943
work_keys_str_mv AT seokwangil chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma
AT jojaecheol chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma
AT kimdajung chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma
AT jeongjeeyeong chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma
AT leesangjin chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma
AT leehosup chronichepatitisbviralactivityenoughtotakeantiviraldrugcouldpredictthesurvivalrateinmalignantlymphoma